Zhejiang Xinguang Pharmaceutical Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Zhejiang Xinguang Pharmaceutical şirketinin toplam hissedar öz sermayesi CN¥817.9M ve toplam borcu CN¥0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla CN¥892.5M ve CN¥74.5M dir. Zhejiang Xinguang Pharmaceutical 'in FAVÖK'ü CN¥30.3M faiz karşılama oranı -2.1 dur. Şirketin CN¥669.6M tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

Borç/özkaynak oranı

CN¥0

Borç

Faiz karşılama oranı	-2.1x
Nakit	CN¥669.61m
Eşitlik	CN¥817.92m
Toplam yükümlülükler	CN¥74.53m
Toplam varlıklar	CN¥892.45m

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Earnings Not Telling The Story For Zhejiang Xinguang Pharmaceutical Co., Ltd. (SZSE:300519) After Shares Rise 38%

Oct 18

Zhejiang Xinguang Pharmaceutical (SZSE:300519) Has Announced That Its Dividend Will Be Reduced To CN¥0.40

May 26

Calculating The Intrinsic Value Of Zhejiang Xinguang Pharmaceutical Co., Ltd. (SZSE:300519)

Apr 16

Zhejiang Xinguang Pharmaceutical Co., Ltd.'s (SZSE:300519) Low P/E No Reason For Excitement

Feb 26

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 300519 'nin kısa vadeli varlıkları ( CN¥753.7M ) kısa vadeli yükümlülüklerini ( CN¥65.5M ) aşıyor.

Uzun Vadeli Yükümlülükler: 300519 şirketinin kısa vadeli varlıkları ( CN¥753.7M ) uzun vadeli yükümlülüklerini ( CN¥9.0M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 300519 borçsuzdur.

Borcun Azaltılması: 300519 un 5 yıl önce borcu yoktu.

Borç Kapsamı: 300519 un borcu yoktur, dolayısıyla işletme nakit akışı tarafından karşılanmasına gerek yoktur.

Faiz Kapsamı: 300519 şirketinin borcu bulunmadığından faiz ödemelerinin karşılanması söz konusu değildir.

Zhejiang Xinguang Pharmaceutical Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

High number of new directors

Third quarter 2024 earnings released: EPS: CN¥0.08 (vs CN¥0.13 in 3Q 2023)

Earnings Not Telling The Story For Zhejiang Xinguang Pharmaceutical Co., Ltd. (SZSE:300519) After Shares Rise 38%

New major risk - Share price stability

Investor sentiment improves as stock rises 34%

Second quarter 2024 earnings released: EPS: CN¥0.017 (vs CN¥0.05 in 2Q 2023)

Zhejiang Xinguang Pharmaceutical Co., Ltd. Announces Board Appointments; Appoints Zhao Kaiyu as Non-Employee Supervisor

New minor risk - Share price stability

Investor sentiment improves as stock rises 26%

Zhejiang Xinguang Pharmaceutical (SZSE:300519) Has Announced That Its Dividend Will Be Reduced To CN¥0.40

Dividend reduced to CN¥0.40

New major risk - Revenue and earnings growth

Full year 2023 earnings released: EPS: CN¥0.40 (vs CN¥0.68 in FY 2022)

Now 27% overvalued

Calculating The Intrinsic Value Of Zhejiang Xinguang Pharmaceutical Co., Ltd. (SZSE:300519)

Investor sentiment deteriorates as stock falls 15%

Zhejiang Xinguang Pharmaceutical Co., Ltd.'s (SZSE:300519) Low P/E No Reason For Excitement

Investor sentiment improves as stock rises 16%

Now 22% overvalued

Investor sentiment deteriorates as stock falls 20%

Third quarter 2023 earnings released: EPS: CN¥0.13 (vs CN¥0.18 in 3Q 2022)

New major risk - Dividend sustainability

Zhejiang Xinguang Pharmaceutical Co., Ltd. Approves the Cash Dividend for 2022, Payment on 30 May 2023

Zhejiang Xinguang Pharmaceutical Co., Ltd. Approves the Cash Dividend

First quarter 2023 earnings released: EPS: CN¥0.19 (vs CN¥0.19 in 1Q 2022)

Investor sentiment improved over the past week

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.18 (vs CN¥0.19 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.11 (vs CN¥0.12 in 2Q 2021)

Zhejiang Xinguang Pharmaceutical Co., Ltd. Approves Profit Distribution for 2021

Less than half of directors are independent

Zhejiang Xinguang Pharmaceutical Co., Ltd. Proposes Final Dividend for 2021

Full year 2021 earnings released: EPS: CN¥0.71 (vs CN¥0.62 in FY 2020)

Investor sentiment deteriorated over the past week

Now 23% undervalued after recent price drop

Investor sentiment improved over the past week

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Now 21% undervalued

Investor sentiment improved over the past week

Now 21% undervalued

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.19 (vs CN¥0.18 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.12 (vs CN¥0.12 in 2Q 2020)

Investor sentiment improved over the past week

Zhejiang Xinguang Pharmaceutical Co., Ltd. Approves Final Cash Dividend on A Shares for the Year 2020, Payable on May 28, 2021

Investor sentiment improved over the past week

Zhejiang Xinguang Pharmaceutical Co., Ltd. Proposes the Final Cash Dividend for 2020

Full year 2020 earnings released: EPS CN¥0.62 (vs CN¥0.59 in FY 2019)

New 90-day low: CN¥13.57

New 90-day low: CN¥16.09

Investor sentiment deteriorated over the past week

New 90-day low: CN¥17.00

Third quarter earnings released

Market bids up stock over the past week

New 90-day high: CN¥23.30

New 90-day high - CN¥20.29

Earnings released

Zhejiang Xinguang Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 26, 2020

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Sağlıklı şirketleri keşfedin